Navigation Links
Stem Cell Licensing Deal Positions Toronto as World Leader in Technology

A $20-million deal announced today to license Canadian stem cell technology in the U.S. underscores the Toronto areas global leadership in stem cell research .

Under the agreement, Tissue Regeneration Therapeutics Inc. (TRT), an emerging Canadian life sciences company, will exclusively license its human umbilical cord perivascular cell (HUCPVC) technology to Stem Cell Authority Ltd. for family stem cell banking in the U.S. The licensing fees and annual minimum royalties will exceed $20-million (Cdn) over the next four years. The technology originated at the University of Toronto and has been offered to the public in Canada since March 2007 through a licensing agreement between TRT and Toronto-based CReAte Cord Blood Bank (CCBB).

Toronto is the first place in the world to bank perivascular mesenchymal stem cells from the human umbilical cord and we are extremely pleased to now be able to provide this opportunity to parents across the U.S., says Professor John E. Davies at U of Ts Institute of Biomaterials and Biomedical Engineering, senior inventor of the technology. This is a great example of how a university can facilitate the translation of professorial research from the university laboratory to commercial reality for the benefit of the public.

Currently, TRT technology is available to the Canadian public through CCBB, which markets HUCPVCs as Peristem. Once the baby is born, a health professional simply collects the cord tissue and places it in a bio-container supplied with a nutrient solution and then ships it to the CReATe laboratories for processing and storage. A technician at the laboratory uses a proprietary process to remove the cells from the cord tissue and stores them for future use. Unlike cord blood stem cells, which can also be harvested, mesenchymal cells are the building blocks for the muscle, bone and connective tissues of the body. HUCPVCs also serve as regulators of the immune system. Published uses of mesenchymal cells in cell therapy include combating auto-immune and inflammatory diseases (Crohns, juvenile diabetes and rheumatoid arthritis), cancer, heart disease and tissue engineering.

While the HUCPVC technology is still in the pre-clinical stage, TRT CEO Dr. Jeffrey Turner says that its development program designed to treat auto-immune and inflammatory diseases offers parents a type of biological life insurance that could one day treat all the diseases mentioned above and more. What excites me is that our growing stem cell company in Canada is now offering its services to the U.S., which is essentially half the world market, Turner says. We are now currently looking to expand into the Middle Eastern and Australian markets.

The HUCPVC breakthrough was announced in 2005 when the Davies research group at the University of Toronto discovered these stem cells in an uncharted part of the umbilical cord the connective tissue immediately surrounding the blood vessels in the cord. The great advantages of this source of mesenchymal stem cells, compared with current techniques using surgically extracted cells from bone marrow, lie in sourcing them from tissue that would otherwise be thrown away at birth, their very rapid proliferation and the huge numbers of harvested stem cells.


Related medicine news :

1. Ranbaxy Signs Licensing, Supply Agreement for Canadian Market
2. Merck Announces Plans for Licensing Atripla Widely in Developing World
3. PSivida, Pfizer Ink $165 Million Licensing Pact
4. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
5. Two New Anesthesia Positions Promise to Ease Surgery Queue
6. Avoid travel to Toronto - WHO
7. WHO Says Toronto Going Back on SARS-Affected List
8. Mysterious viral outbreak in Toronto, influenza ruled out
9. Satellite Clinic To Be Set Up in Toronto By Ohio-Based Cleveland Clinic
10. IOF World Congress On Osteoporosis To Be Held In Toronto
11. Hepatitis Scare in Toronto
Post Your Comments:

(Date:11/27/2015)... , ... November 27, 2015 , ... ... safe and convenient way to dispense prescription medications at home, so he invented ... way to monitor and dispense prescription medications. In doing so, it could help ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Lizzie’s Lice ... The company is offering customers 10% off of their purchase of lice treatment product. ... at full price. According to a company spokesperson. “Finding lice is a sure way ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set of ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease ...
(Date:11/27/2015)... ... 2015 , ... Consistent with the Radiology Business Management ... Radiology Marketing Programs meeting will showcase some of the best 2015 radiology ... Palace in Las Vegas with a pre-conference session on a collaborative approach for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare ... 7% over 2015-2016. Latin America has ... , (excluding Japan ), is second ... continues to face increased healthcare expenditure. In 2013-2014, total ... declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. In ...
Breaking Medicine Technology: